Wegovy and Bloody Stool: What the Evidence Says

What the STEP 1 trial and UK prescribing data actually recorded

The pivotal STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity over 68 weeks on semaglutide 2.4mg. The documented gastrointestinal side effects were predominantly nausea, vomiting, diarrhoea and constipation, all clustered in the early weeks and after dose increases, then settling for most participants. Rectal bleeding or bloody stool did not feature in the trial's common adverse-event reporting.

The UK prescribing information, as held on the electronic Medicines Compendium, lists gastrointestinal disorders as the most frequent category of side effect, but blood in stool is not among the reactions flagged as common or very common for Wegovy. That does not mean it cannot happen, it means it is not a recognised pattern of the medicine itself. When it does occur in someone taking Wegovy, the cause usually lies elsewhere and needs investigating on its own terms.

This distinction matters practically. Patients sometimes assume that any new symptom during a course of treatment must be caused by the treatment. With a medicine that changes gut motility as meaningfully as semaglutide does, the gut is under extra scrutiny, which can make pre-existing or coincidental conditions more noticeable. The evidence base simply does not support attributing visible rectal bleeding to the drug without a clinical assessment ruling out other explanations, and what the evidence does and does not say about whether semaglutide can cause blood in stool is explored in more detail on a dedicated page.

How Wegovy's effects on the gut could indirectly contribute

Semaglutide slows gastric emptying and alters gut transit time. For many people that means constipation, particularly early in treatment or after a dose step up. Persistent straining from constipation is a well-documented cause of haemorrhoids and anal fissures, both of which produce bright red blood on toilet paper or in the bowl. In that narrow sense, Wegovy's effect on the gut could create conditions that lead to minor lower-GI bleeding, even if the medicine itself is not the direct cause.

The NHS medicines page for semaglutide advises patients to tell their doctor or pharmacist straight away if they develop severe or persistent stomach pain, particularly if it reaches into the back, that combination is a recognised warning sign for acute pancreatitis, which the MHRA highlighted in a Drug Safety Update in January 2026 as an infrequent but potentially serious risk with GLP-1 medicines. Pancreatitis itself can cause GI bleeding in rare cases. This is one reason why abdominal pain alongside any unusual stool changes should be taken seriously rather than attributed simply to the medicine's known mild GI profile.

Separately, questions about stool colour variations come up regularly alongside this topic, and if you are wondering whether Wegovy can cause black stool and what a darker appearance during treatment might mean, that page covers the clinical significance in detail. A darker appearance can point to bleeding higher in the digestive tract, which carries different clinical significance and is worth reading about alongside this page.

When bloody stool during Wegovy treatment needs urgent attention

A question our prescribers hear most weeks is some version of: "I noticed blood, do I need to stop the injection?" The honest answer is that stopping or continuing Wegovy is secondary to getting the bleeding assessed. The priority is working out where the blood is coming from.

Bright red blood that appears only on the tissue after wiping, without pain, is most often haemorrhoidal and usually not a medical emergency, but it still warrants a GP review, especially if it is new and you are on a prescription medicine. Dark, tarry or maroon-coloured stool, blood mixed into the stool rather than coating it, or bleeding accompanied by abdominal pain, dizziness or weakness are signs that need same-day attention. Contact NHS 111 or go to your nearest urgent treatment centre. Do not wait for your next scheduled prescriber review.

From a clinical governance perspective, it is also worth noting that a prescriber cannot safely continue to titrate a Wegovy dose while a significant undiagnosed symptom is under investigation. If you are being supported through a private service like nume's Wegovy programme, the prescribing team needs to know about any new symptoms before your next review, that is what the 7-day aftercare line is for. Reach the team via the contact page or, if symptoms are urgent, go directly to NHS services.

Getting the right clinical input

Wegovy is a prescription-only medicine and every person taking it should have a prescriber they can reach with questions exactly like this one. If your bowel habits have changed noticeably since starting semaglutide (more constipation, looser stools, or anything involving blood) document when it started, what the blood looks like, and whether anything else has changed. That information helps a clinician distinguish a benign local cause from something that needs investigation.

For people who have not yet started treatment and are weighing up the full side-effect picture before making a decision, a free consultation is the right first step. A real clinician reviews every application, and questions about your GI history are a standard part of that assessment. The prescriber can flag whether any existing gut conditions change the risk profile before a pen is ever dispensed. You can read more about the treatment options available through our prescribing service, or explore the semaglutide overview for a broader picture of how the medicine works. If you have already started and have concerns about cost or continuity of supply, the Wegovy pricing page covers what to expect from a legitimate private provider. For wider questions about the full weight management approach, the weight loss overview is a useful starting point.